Study #2023-0911
A phase I study investigating the combination of the menin inhibitor Ziftomenib with Venetoclax and Gemtuzumab Ozogamicin in pediatric patients with acute myeloid leukemia.
MD Anderson Study Status
Enrolling
Treatment Agent
Venetoclax, Gemtuzumab, Ziftomenib
Description
To find the recommended dose of ziftomenib in combination with gemtuzumab ozogamicin and venetoclax that can be given to pediatric participants who have relapsed or refractory AML or MPAL.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Acute Myeloid Leukemia
Study phase:
Phase I
Physician name:
Branko Cuglievan
Department:
Pediatrics
For general questions about clinical trials:
1-833-731-1107
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.